User profiles for Neil Rajan

Neil Rajan

Newcastle University
Verified email at ncl.ac.uk
Cited by 1653

Developmental cell programs are co-opted in inflammatory skin disease

…, J Bacardit, PH Jones, EA O'Toole, GS Ogg, N Rajan… - Science, 2021 - science.org
INTRODUCTION Human skin provides vital protection from water loss and from external insult
through structural adaptations and interplay with the innate and adaptive immune systems…

Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas

N Rajan, JAA Langtry - Clinical and experimental dermatology, 2006 - academic.oup.com
Rajan, JAA Langtry, Generalized exacerbation of psoriasis associated with imiquimod
cream treatment of superficial basal cell carcinomas, Clinical and Experimental Dermatology, …

CYLD is a causative gene for frontotemporal dementia – amyotrophic lateral sclerosis

…, AA Luty, PR Schofield, WS Brooks, N Rajan… - Brain, 2020 - academic.oup.com
Frontotemporal dementia and amyotrophic lateral sclerosis are clinically and pathologically
overlapping disorders with shared genetic causes. We previously identified a disease locus …

Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study

…, R Katugampla, C Blasdale, S Lateo, N Rajan… - Journal of the American …, 2016 - Elsevier
Background Pyoderma gangrenosum (PG) is an uncommon dermatosis with a limited evidence
base for treatment. Objective We sought to estimate the effectiveness of topical therapies …

[HTML][HTML] Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations

…, CJ Stewart, CA Lamb, RA Speight, N Rajan… - Frontiers in …, 2023 - frontiersin.org
Checkpoint inhibitors (CPIs) are monoclonal antibodies which, by disrupting interactions of
immune checkpoint molecules with their ligands, block regulatory immune signals otherwise …

Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours

N Rajan, R Elliott, O Clewes, A Mackay, JS Reis-Filho… - Oncogene, 2011 - nature.com
Individuals with germline mutations in the tumour-suppressor gene CYLD are at high risk of
developing disfiguring cutaneous appendageal tumours, the defining tumour being the …

CYLD in health and disease

…, J Inns, C Dobson-Stone, N Rajan - Disease Models & …, 2023 - journals.biologists.com
CYLD lysine 63 deubiquitinase (CYLD) is a ubiquitin hydrolase with important roles in immunity
and cancer. Complete CYLD ablation, truncation and expression of alternate isoforms, …

Inherited cylindromas: lessons from a rare tumour

N Rajan, A Ashworth - The lancet oncology, 2015 - thelancet.com
Cylindroma is a rare skin tumour that is inherited in several skin-tumour syndromes caused
by germline mutations in the tumour suppressor gene, CYLD. In this Review, we provide …

Porocarcinoma: a review

…, B Bodegraven, S Vernon, N Rajan… - Clinical and …, 2022 - academic.oup.com
From the first report in 1969 to the present day, diagnosis of eccrine porocarcinoma, also
known simply as porocarcinoma (PC), remains a challenge. This review presents a concise …

Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction

N Rajan, JAA Langtry, A Ashworth… - Archives of …, 2009 - jamanetwork.com
Objectives To comprehensively ascertain the extent and severity of clinical features in affected
individuals from 2 large families with proven heterozygous mutations in theCYLDlocus …